Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM. Neuropsychiatr Dis Trea. 2014;10:391–401. On page 393, Figure 1, “Maintenance period (month 6 to 24)” should be “Maintenance period (month 4 to 24)”; &...
Guardado en:
Autores principales: | Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/09ce8a88547845a3adad92e246cc5c0a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Ben Seltzer
Publicado: (2009) -
Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study
por: Zhang Z, et al.
Publicado: (2012) -
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
por: Richard A Hansen, et al.
Publicado: (2008) -
Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease
por: Woo FY, et al.
Publicado: (2015) -
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
por: Kano O, et al.
Publicado: (2013)